OVERSEA CHINESE BANKING Corp Ltd purchased a new position in shares of DaVita Inc. (NYSE:DVA - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,373 shares of the company's stock, valued at approximately $983,000.
A number of other hedge funds also recently added to or reduced their stakes in DVA. MML Investors Services LLC raised its stake in shares of DaVita by 1.3% in the third quarter. MML Investors Services LLC now owns 5,300 shares of the company's stock valued at $869,000 after acquiring an additional 68 shares in the last quarter. Exchange Traded Concepts LLC raised its position in DaVita by 8.3% in the 4th quarter. Exchange Traded Concepts LLC now owns 891 shares of the company's stock valued at $133,000 after purchasing an additional 68 shares in the last quarter. Impact Partnership Wealth LLC boosted its stake in shares of DaVita by 3.7% in the 4th quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company's stock valued at $290,000 after buying an additional 70 shares during the period. Contravisory Investment Management Inc. grew its position in shares of DaVita by 1.2% during the fourth quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company's stock worth $910,000 after buying an additional 73 shares in the last quarter. Finally, Nilsine Partners LLC increased its stake in shares of DaVita by 0.8% during the fourth quarter. Nilsine Partners LLC now owns 11,160 shares of the company's stock worth $1,669,000 after buying an additional 92 shares during the period. 90.12% of the stock is currently owned by institutional investors and hedge funds.
DaVita Stock Performance
NYSE:DVA traded up $2.41 during trading hours on Monday, reaching $150.56. 704,916 shares of the company's stock were exchanged, compared to its average volume of 783,862. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The firm has a market capitalization of $12.04 billion, a price-to-earnings ratio of 14.02, a P/E/G ratio of 1.07 and a beta of 0.99. DaVita Inc. has a 1-year low of $125.64 and a 1-year high of $179.60. The company has a 50-day moving average of $158.53 and a 200 day moving average of $157.56.
DaVita (NYSE:DVA - Get Free Report) last announced its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Research analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on the stock. StockNews.com downgraded shares of DaVita from a "buy" rating to a "hold" rating in a research report on Friday. Cowen reissued a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a report on Friday, February 21st. Finally, Barclays lifted their price target on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $166.33.
Read Our Latest Analysis on DaVita
DaVita Company Profile
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Stories
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
